Patents by Inventor Bernard Christophe

Bernard Christophe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine and pyrazine derivatives -083
    Patent number: 8017611
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: September 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
  • PYRIDINE COMPOUNDS
    Publication number: 20110166139
    Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
    Type: Application
    Filed: June 15, 2009
    Publication date: July 7, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
  • Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
    Patent number: 7947676
    Abstract: The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: May 24, 2011
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • CHROMENONE DERIVATIVES
    Publication number: 20110098271
    Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 22, 2010
    Publication date: April 28, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
  • PYRIMIDINE DERIVATIVES
    Publication number: 20110046108
    Abstract: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
    Type: Application
    Filed: January 25, 2007
    Publication date: February 24, 2011
    Applicant: AstraZeneca AB
    Inventors: Jason Grant Kettle, Jon Read, Andrew Leach, Bernard Christophe Barlaam, Richard Ducray, Christine Marie Paul Lambert-Van Der Brempt
  • Quinazoline derivatives as antiproliferative agents
    Patent number: 7838530
    Abstract: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: November 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 7820683
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Bernard Christophe Barlaam, Richard Ducray
  • 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    Publication number: 20100222344
    Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: November 29, 2006
    Publication date: September 2, 2010
    Inventor: Bernard Christophe Barlaam
  • Pyrimidine derivatives for inhibiting Eph receptors
    Patent number: 7718653
    Abstract: A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic ring which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: May 18, 2010
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
    Patent number: 7544675
    Abstract: The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: March 29, 2003
    Date of Patent: June 9, 2009
    Assignee: UCB, S.A.
    Inventors: Laurent Provins, Berend Jan Van Keulen, John Surtees, Patrice Talaga, Bernard Christophe
  • PYRIDINE AND PYRAZINE DERIVATIVES - 083
    Publication number: 20090118305
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
  • NOVEL PYRIMIDINE DERIVATIVES 965
    Publication number: 20090054428
    Abstract: The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R1, Q, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    Type: Application
    Filed: July 17, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray
  • 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20090048251
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: September 14, 2006
    Publication date: February 19, 2009
    Inventors: Robert Hugh Bradbury, Bernard Christophe Barlaam, Richard Ducray
  • NOVEL PYRIMIDINE DERIVATIVES - 816
    Publication number: 20090036440
    Abstract: The invention concerns pyrimidine compounds of Formula I, or a pharmaceutically acceptable salt thereof, where A1, A2 A3, R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    Type: Application
    Filed: April 25, 2008
    Publication date: February 5, 2009
    Applicant: AstraZeneca AB
    Inventors: Bernard Christophe BARLAAM, Richard DUCRAY
  • QUINAZOLINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE
    Publication number: 20090029968
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: November 29, 2006
    Publication date: January 29, 2009
    Inventors: Bernard Christophe Barlaam, Robert Hugh Bradbury, Richard Ducray
  • PYRIMIDINE DERIVATIVES 934
    Publication number: 20090023719
    Abstract: A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.
    Type: Application
    Filed: July 16, 2008
    Publication date: January 22, 2009
    Applicant: Astrazeneca AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • NOVEL PYRIMIDINE DERIVATIVES 698
    Publication number: 20080242663
    Abstract: The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    Type: Application
    Filed: February 28, 2008
    Publication date: October 2, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Susan Elizabeth Ashton, Darren Anthony Edward Cross, Simon John East, Jason Grant Kettle, Mark Andrew Pearson, Stephen Robert Wedge, Bernard Christophe Barlaam, Richard Ducray, Stuart Charles Purkiss
  • Pyrazolopyrimidine Compounds as Antitumor Agents
    Publication number: 20080108613
    Abstract: The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    Type: Application
    Filed: December 12, 2005
    Publication date: May 8, 2008
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • Quinazoline Derivatives
    Publication number: 20080096881
    Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 15, 2004
    Publication date: April 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Laurent Francois Andre Hennequin, Bernard Christophe Barlaam, Robert Hugh Bradbury
  • Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)
    Patent number: 7342020
    Abstract: Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: March 11, 2008
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Nicholas John Newcombe, Howard Tucker, David Waterson